1/ Newer data is reshaping post-MI Ξ²-blocker strategy. REBOOT shows no benefit when EF>40% in patients receiving modern invasive/medical therapy, while pooled data from BETAMI, DANBLOCK, and CAPITAL-RCT suggest benefit in the EF 40β49% range. #medsky #pharmsky #emimcc #cardiosky
5 days ago